XTX Topco Ltd Makes New $1.61 Million Investment in BeiGene, Ltd. (NASDAQ:BGNE)

XTX Topco Ltd bought a new position in BeiGene, Ltd. (NASDAQ:BGNE - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 7,191 shares of the company's stock, valued at approximately $1,614,000.

A number of other institutional investors have also bought and sold shares of the business. Blue Trust Inc. raised its position in shares of BeiGene by 156.3% during the third quarter. Blue Trust Inc. now owns 123 shares of the company's stock valued at $28,000 after buying an additional 75 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in shares of BeiGene during the 3rd quarter valued at about $36,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of BeiGene during the 3rd quarter valued at about $67,000. SG Americas Securities LLC purchased a new position in shares of BeiGene during the third quarter valued at about $105,000. Finally, PFG Investments LLC bought a new stake in shares of BeiGene in the third quarter worth about $210,000. Hedge funds and other institutional investors own 48.55% of the company's stock.

BeiGene Trading Up 1.0 %

Shares of BGNE traded up $2.00 during mid-day trading on Monday, reaching $207.62. 512,842 shares of the company's stock traded hands, compared to its average volume of 276,008. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. The stock's 50-day moving average is $211.48 and its two-hundred day moving average is $186.29. BeiGene, Ltd. has a 12 month low of $126.97 and a 12 month high of $248.16. The stock has a market cap of $20.23 billion, a P/E ratio of -25.20 and a beta of 0.57.

BeiGene (NASDAQ:BGNE - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share for the quarter, missing analysts' consensus estimates of ($1.11) by ($0.04). BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The business had revenue of $1 billion during the quarter, compared to analysts' expectations of $983.26 million. During the same quarter in the previous year, the business earned $2.01 EPS. The business's revenue for the quarter was up 28.2% on a year-over-year basis. Research analysts forecast that BeiGene, Ltd. will post -5.64 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on BGNE. StockNews.com lowered BeiGene from a "buy" rating to a "hold" rating in a research note on Thursday, November 21st. TD Cowen increased their price objective on shares of BeiGene from $254.00 to $260.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. JPMorgan Chase & Co. boosted their target price on shares of BeiGene from $200.00 to $235.00 and gave the stock an "overweight" rating in a report on Tuesday, October 22nd. Morgan Stanley reaffirmed an "overweight" rating and issued a $300.00 price target on shares of BeiGene in a report on Tuesday, December 3rd. Finally, JMP Securities began coverage on BeiGene in a research note on Wednesday, September 18th. They set a "market outperform" rating and a $288.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $253.69.

Insider Buying and Selling

In other news, COO Xiaobin Wu sold 500 shares of the firm's stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $200.00, for a total transaction of $100,000.00. Following the transaction, the chief operating officer now owns 4,500 shares in the company, valued at approximately $900,000. This trade represents a 10.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Xiaodong Wang sold 40,468 shares of BeiGene stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $190.10, for a total value of $7,692,966.80. The disclosure for this sale can be found here. Insiders have sold 57,845 shares of company stock valued at $11,514,300 in the last 90 days. Company insiders own 7.43% of the company's stock.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.